Clinical Trial Update: Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib for persistent or recurrent cervical cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Squamous Cell Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer | Phase 2 | Status: COMPLETED